nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

10.08.2023 | Original Article

Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China

verfasst von: Jiying Qi, Ping He, Huayan Yao, Wen Sun, Ping Lu, Zizheng Zhang, Bin Cui, Guang Ning

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

The association of insulin glargine with overall and site-specific cancer risk remains uncertain. This study aims to provide relevant evidence from mainland China.

Methods

Based on the Shanghai Link Healthcare Database, patients newly treated with insulin glargine or neutral protamine Hagedorn (NPH) insulin between January 1, 2013 and December 31, 2020 were identified and followed up until December 31, 2021. In addition to the original cohort, we created a 1:1 propensity score-matched cohort with balanced baseline characteristics. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident cancers, comparing insulin glargine with NPH insulin.

Results

A total of 26,810 insulin glargine users and 47,765 NPH insulin users were enrolled in the final analysis. During a median follow-up of 4.18 years, 3903 patients developed cancer. Including a 1-year lag period, insulin glargine use was not associated with increased cancer risk compared to NPH insulin use in both the original cohort (HR 1.02, 95% CI 0.95–1.10) and the propensity score-matched cohort (HR 1.01, 95% CI 0.94–1.09). In stratified analyses by sex, age, and cancer site, as well as in sensitivity analyses at different lag periods, the estimated cancer risk, although fluctuating, remained uncorrelated without any substantial change.

Conclusion

Insulin glargine is not associated with the risk of overall and site-specific cancers compared to NPH insulin among patients with type 2 diabetes mellitus.

Nur mit Berechtigung zugänglich

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21. https://doi.org/10.3322/caac.20078.CrossRefPubMed

Qi J, He P, Yao H, Song R, Ma C, Cao M, Cui B, Ning G. Cancer risk among patients with type 2 diabetes: a real-world study in Shanghai, China. J Diabetes. 2019;11:878–83. https://doi.org/10.1111/1753-0407.12926.CrossRefPubMed

Hemkens L, Grouven U, Bender R, Günster C, Gutschmidt S, Selke G, Sawicki P. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44. https://doi.org/10.1007/s00125-009-1418-4.CrossRefPubMedPubMedCentral

Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54. https://doi.org/10.1007/s00125-009-1444-2.CrossRefPubMed

Colhoun H. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65. https://doi.org/10.1007/s00125-009-1453-1.CrossRefPubMedPubMedCentral

Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77. https://doi.org/10.1007/s00125-009-1440-6.CrossRefPubMed

Ljung R, Talbäck M, Haglund B, Jonasson J, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a three-year population-based observation. Acta oncologica (Stockholm, Sweden). 2011;50:685–93. https://doi.org/10.3109/0284186x.2011.558913.CrossRefPubMed

Morden N, Liu S, Smith J, Mackenzie T, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011;34:1965–71. https://doi.org/10.2337/dc11-0699.CrossRefPubMedPubMedCentral

Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS. Cancer risk associated with insulin glargine among adult type 2 diabetes patients–a nationwide cohort study. PLoS One. 2011;6:e21368. https://doi.org/10.1371/journal.pone.0021368.ADSCrossRefPubMedPubMedCentral

10.

Buchs AE, Silverman BG. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism. 2011;60:1379–85. https://doi.org/10.1016/j.metabol.2011.05.002.CrossRefPubMed

11.

Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011;54:2254–62. https://doi.org/10.1007/s00125-011-2190-9.CrossRefPubMed

12.

Ruiter R, Visser L, van Herk-Sukel M, Coebergh J, Haak H, Geelhoed-Duijvestijn P, Straus S, Herings R, Stricker B. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55:51–62. https://doi.org/10.1007/s00125-011-2312-4.CrossRefPubMed

13.

Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard M, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012;55:644–53. https://doi.org/10.1007/s00125-011-2429-5.CrossRefPubMedPubMedCentral

14.

Kostev K. Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin. Diabetologia. 2012;55:1554–5. https://doi.org/10.1007/s00125-012-2497-1.CrossRefPubMed

15.

Lind M, Fahlen M, Eliasson B, Oden A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes. 2012;6:53–9. https://doi.org/10.1016/j.pcd.2011.10.004.CrossRefPubMed

16.

Ljung R, Talbäck M, Haglund B, Jonasson J, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of breast cancer-a four-year population-based observation. Acta oncologica (Stockholm, Sweden). 2012;51:400–2. https://doi.org/10.3109/0284186x.2011.624118.CrossRefPubMed

17.

van Staa T, Patel D, Gallagher A, de Bruin M. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia. 2012;55:654–65. https://doi.org/10.1007/s00125-011-2390-3.CrossRefPubMed

18.

Fagot J, Blotière P, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: a French nationwide cohort study based on national administrative databases. Diabetes Care. 2013;36:294–301. https://doi.org/10.2337/dc12-0506.CrossRefPubMedPubMedCentral

19.

Stürmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, Macdonald E, Wang R, Lavange LM, Pate V, Buse JB. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care. 2013;36:3517–25. https://doi.org/10.2337/dc13-0263.CrossRefPubMedPubMedCentral

20.

Lim S, Stember K, He W, Bianca P, Yelibi C, Marquis A, Stürmer T, Buse J, Meigs J. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. PloS one. 2014;9:e109433. https://doi.org/10.1371/journal.pone.0109433.ADSCrossRefPubMedPubMedCentral

21.

Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, Ferrara A. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013;36:3953–60. https://doi.org/10.2337/dc13-0140.CrossRefPubMedPubMedCentral

22.

Peeters PJ, Bazelier MT, Leufkens HG, Auvinen A, van Staa TP, de Vries F, De Bruin ML. Insulin glargine use and breast cancer risk: associations with cumulative exposure. Acta Oncol. 2016;55:851–8. https://doi.org/10.3109/0284186x.2016.1155736.CrossRefPubMedPubMedCentral

23.

Wu J, Azoulay L, Majdan A, Boivin J, Pollak M, Suissa S. Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes. J Clin Oncol. 2017;35:3647–53. https://doi.org/10.1200/jco.2017.73.4491.CrossRefPubMed

24.

But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A, Starup-Linde J, Schmidt MK, Furu K, de Vries F, Karlstad O, Ekstrom N, Haukka J. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia. 2017;60:1691–703. https://doi.org/10.1007/s00125-017-4312-5.CrossRefPubMedPubMedCentral

25.

Pradhan R, Yin H, Yu O, Azoulay L. The use of long-acting insulin analogs and the risk of colorectal cancer among patients with type 2 diabetes: a population-based cohort study. Drug Saf. 2020;43:103–10. https://doi.org/10.1007/s40264-019-00892-5.CrossRefPubMed

26.

Simó R, Plana-Ripoll O, Puente D, Morros R, Mundet X, Vilca L, Hernández C, Fuentes I, Procupet A, Tabernero J, Violán C. Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PloS one. 2013;8:e79968. https://doi.org/10.1371/journal.pone.0079968.ADSCrossRefPubMedPubMedCentral

27.

Grimaldi-Bensouda L, Cameron D, Marty M, Barnett A, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin J, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care. 2014;37:134–43. https://doi.org/10.2337/dc13-0695.CrossRefPubMed

28.

Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella C. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33:1997–2003. https://doi.org/10.2337/dc10-0476.CrossRefPubMedPubMedCentral

29.

Wu J, Filion K, Azoulay L, Doll M, Suissa S. Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies. Diabetes Care. 2016;39:486–94. https://doi.org/10.2337/dc15-1816.CrossRefPubMed

30.

Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374:511–3. https://doi.org/10.1016/s0140-6736(09)61307-6.CrossRefPubMed

31.

Tamim H, Monfared A, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidem Dr S. 2007;16:250–8. https://doi.org/10.1002/pds.1360.CrossRef

32.

Johnson J, Bowker S, Richardson K, Marra C. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. https://doi.org/10.1007/s00125-011-2242-1.CrossRefPubMed

33.

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79. https://doi.org/10.1002/sim.6607.MathSciNetCrossRefPubMedPubMedCentral

34.

Rosenstock J, Fonseca V, McGill J, Riddle M, Hallé J, Hramiak I, Johnston P, Davis M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52:1971–3. https://doi.org/10.1007/s00125-009-1452-2.CrossRefPubMedPubMedCentral

35.

Home P, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499–506. https://doi.org/10.1007/s00125-009-1530-5.CrossRefPubMedPubMedCentral

36.

Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28. https://doi.org/10.1056/NEJMoa1203858.CrossRefPubMed

37.

Bordeleau L, Yakubovich N, Dagenais G, Rosenstock J, Probstfield J, Chang YuP, Ryden L, Pirags V, Spinas G, Birkeland K, Ratner R, Marin-Neto J, Keltai M, Riddle M, Bosch J, Yusuf S, Gerstein H. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care. 2014;37:1360–6. https://doi.org/10.2337/dc13-1468.CrossRefPubMed

38.

Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, Belfiore A, Vigneri R. Long-acting insulin analogs and cancer. Nutr Metab Cardiovasc Dis. 2018;28:436–43. https://doi.org/10.1016/j.numecd.2018.02.010.CrossRefPubMed

39.

Vigneri R, Sciacca L, Vigneri P. Rethinking the relationship between insulin and cancer. Trends Endocrinol Metab. 2020;31:551–60. https://doi.org/10.1016/j.tem.2020.05.004.CrossRefPubMed

40.

Ter Braak B, Siezen C, Kannegieter N, Koedoot E, van de Water B, van der Laan J. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. Arch Toxicol. 2014;88:953–66. https://doi.org/10.1007/s00204-014-1201-2.CrossRefPubMed

41.

Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999–1005. https://doi.org/10.2337/diabetes.49.6.999.CrossRefPubMed

42.

Gallagher E, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia. 2016;59:2018–25. https://doi.org/10.1007/s00125-016-4000-x.CrossRefPubMedPubMedCentral

43.

Yoshida K, Solomon D, Kim S. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11:437–41. https://doi.org/10.1038/nrrheum.2015.30.CrossRefPubMedPubMedCentral

Titel: Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China
verfasst von: Jiying Qi
Ping He
Huayan Yao
Wen Sun
Ping Lu
Zizheng Zhang
Bin Cui
Guang Ning
Publikationsdatum: 10.08.2023
Verlag: Springer India
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe 1/2024
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-023-01230-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China

Abstract

Objective

Methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Diabetes self-care activities among patients with type 2 diabetes: A systematic review and meta-analysis

Correction to: Basic fibroblast growth factor alleviates metabolic abnormalities in the heart of streptozotocin-induced diabetic rats

Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus

Impaired glucolipid metabolism in gestational diabetes mellitus with T variation of TCF7L2 rs7903146: A case–control study

Changes of sweat gland function in type 2 diabetes mellitus patients with peripheral neuropathy

Diabetic retinopathy screening guidelines for Physicians in India: position statement by the Research Society for the Study of Diabetes in India (RSSDI) and the Vitreoretinal Society of India (VRSI)-2023